Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991501 | 0.87 | HPGD (0.46) | — | |
| SCHEMBL23605917 | 0.86 | GAA (0.52) | PTPN1 | |
| SCHEMBL21991836 | 0.83 | LMNA (0.54) | FFAR1FFAR4PDK2 | |
| SCHEMBL21991801 | 0.83 | PDE3B (0.42) | FFAR1FFAR4 | |
| SCHEMBL31457737 | 0.82 | PTPN1 (0.51) | BRD4PTPN1TNF | |
| SCHEMBL26654659 | 0.82 | PTPN1 (0.51) | BRD4PTPN1TNF | |
| SCHEMBL24418987 | 0.80 | HIF1A (0.40) | — | |
| SCHEMBL21991935 | 0.80 | FBP1 (0.41) | FFAR1FFAR4 | |
| SCHEMBL21992555 | 0.79 | MAPT (0.60) | RECQLLTA4H | |
| SCHEMBL21991766 | 0.78 | LTA4H (0.52) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | BRD4 3043/4885FFAR1 147/4885FFAR4 173/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | BRD4 3043/4885FFAR1 147/4885FFAR4 173/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | BRD4 3043/4885FFAR1 147/4885FFAR4 173/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | BRD4 3043/4885FFAR1 147/4885FFAR4 173/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | BRD4 3043/4885FFAR1 147/4885FFAR4 173/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | BRD4 3043/4885FFAR1 147/4885FFAR4 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.